Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46493 | 0.80 | CYP3A4 (0.48) | NR4A2CYP3A4MAPTLMNARAB9A | |
| SCHEMBL44551 | 0.76 | KMO (0.50) | HTTNR4A2LMNAALDH1A1RAB9A | |
| SCHEMBL15504853 | 0.69 | CYP1A2 (0.68) | HTTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15513802 | 0.69 | CYP1A2 (0.68) | HTTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL45335 | 0.69 | ALDH1A1 (0.50) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL44170 | 0.69 | GAA (0.41) | HTTNR4A2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL45433 | 0.69 | GLA (0.37) | NR4A2MAPTALDH1A1KMT2ARAB9A | |
| SCHEMBL13844861 | 0.68 | KDM4E (0.38) | MAPTALDH1A1RAB9ANPC1KDM4E | |
| SCHEMBL44288 | 0.68 | CHEK1 (0.41) | NR4A2CYP2C9LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL15504851 | 0.68 | TDP1 (0.60) | HTTMAPTLMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2214669-B1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2015-04-01 | — | — | EP | disclosed |
| WO-2011137587-A1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2011-11-10 | — | — | WO | disclosed |
| US-7868001-B2 | Cytokine inhibitors | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2011-01-11 | — | — | US | disclosed |
| US-7868001-B2 | Cytokine inhibitors | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2011-01-11 | — | — | US | disclosed |
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (CN) | 2009-05-07 | — | — | US | disclosed |
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (CN) | 2009-05-07 | — | — | US | disclosed |
| WO-2009059162-A1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | IL1B, IL1A, IL17A | HTT 4775/4885NR4A2 2721/4885CYP1A2 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.